Peter DeMuth

Peter DeMuth

Company: Elicio Therapeutics

Job title: Vice President - Research


Lymph-Node Targeted TLR9 Agonists Enable Potent Cellular Immune Responses Against Cancer & Infectious Disease 4:00 pm

Dissecting what exactly is lacking in the current models and bridging the translation gap Exploring how we can design/strategize/use the right models to really represent what we want Exploring what constitutes sensitivity Using models to predict the severe side effects seen in humans Understanding what the best setting is to do efficacy/new target discovery for…Read more

day: Day One

© Copyright 2022 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.